凯力康治疗急性脑梗死的临床疗效及安全性观察

目的:观察凯力康治疗急性脑梗死的临床疗效及安全性。方法:急性脑梗死患者38例,随机分为治疗组和对照组各19例,2组均予对症治疗,治疗组加用凯力康治疗14d。于治疗前后评定NIHSS评分、BI评分及临床疗效,并监测不良反应。结果:治疗组治疗14d后NIHSS评分、3个月时BI评分及临床有效率与对照组比较差异有统计学意义(P<0.05),2组均无明显不良反应。结论:凯力康治疗急性脑梗死安全有效,能显著改善预后。

The Evaluation of Efficacy and Safety of Human Urinary Kallidinogenase in Treatment of Acute Cerebral Infarction

Objective:To investigate the efficacy and safety of Human Urinary Kallidinogenase in the treatment of acute cerebral infarction(ACI).Methods:Thirty-eight patients with ACI were randomly divided into the groups treatment and control.All the patients were given a basic therapy.Human Urinary Kallidinogenase was administrated to the patients in the treatment group for 14 days in addition to the basic therapy.All the patients have been evaluated by NIHSS and BI at days 14 and 90 after the treatment.Side-effects were monitored at the same time.Results:After the therapy,there were significant differences(P<0.05)in scores of NIHSS and BI between the two groups.No serious side effects were reported.Conclusion:Human Urinary Kallidinogenase may be effective and safe in treating patients with ACI.